Craft

Cartesian Therapeutics

Stock Price

$22.4

2024-10-29

Market Capitalization

$536.3 M

2024-10-29

Revenue

$38.9 M

FY, 2024

Cartesian Therapeutics Summary

Company Summary

Overview
Cartesian Therapeutics (formerly Selecta Biosciences) is a clinical-stage biopharmaceutical company advancing a differentiated product pipeline to modulate the immune system. It operates through one segment: research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Type
Public
Status
Active
Founded
2007
HQ
Watertown, MA, US | view all locations
Website
http://selectabio.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Carsten Brunn

    Carsten Brunn, President and CEO

    • Carrie S. Cox

      Carrie S. Cox, Chairman

      • Timothy Barabe

        Timothy Barabe, Director

        • Lloyd Johnston

          Lloyd Johnston, Chief Operations Officer

        LocationsView all

        1 location detected

        • Watertown, MA HQ

          United States

          65 Grove St

        Cartesian Therapeutics Financials

        Summary Financials

        Revenue (Q1, 2025)
        $1.1M
        Net income (Q1, 2025)
        ($17.7M)
        Cash (Q1, 2025)
        $180.4M
        EBIT (Q1, 2025)
        ($21.9M)
        Enterprise value
        $369.9M

        Footer menu